Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
NCT ID: NCT05725057
Last Updated: 2025-10-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
31 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-11-30
Study Completion Date
2024-10-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an additional 30 days for safety.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
NCT05965089
Healthy Volunteers
Mild to Moderate Psoriasis
COMPLETED
PHASE1
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT01208090
Psoriasis
COMPLETED
PHASE2
ACT-128800 in Psoriasis
NCT00852670
Plaque Psoriasis
COMPLETED
PHASE2
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
NCT03835481
Psoriasis
TERMINATED
PHASE2
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
NCT03706209
Psoriasis
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Phase 2a Proof of Concept randomized, double-blind, placebo-controlled study to investigate the safety and tolerability of AX-158 in patients with mild to moderate Psoriasis. Participants will be randomized 2:1 to receive AX-158 or Placebo. A total of 30 participants will be treated for 28 days and followed for an additional 30 days for safety.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Psoriasis
Plaque Psoriasis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Prospective, randomized, multicenter, double-blind, placebo-controlled study
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AX-158 - (Arm 1)
AX-158 Dosage:5 mg capsules Form: Capsule Frequency - 2 capsules daily taken orally Duration - 28 consecutive days
Group Type
ACTIVE_COMPARATOR
AX-158
Intervention Type
DRUG
Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
Placebo - (Arm 2)
Placebo Dosage: NA Form: Capsule Frequency: 2 capsules daily taken orally Duration: 28 consecutive days
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AX-158
Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
Intervention Type
DRUG
Placebo
Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Able to understand and willing to provide informed consent and able to comply with the study procedures and restrictions.
2. Diagnosis of plaque psoriasis for ≥3 months at time of screening.
3. Male or female subjects age 18 to 60 years, inclusive, at the time of informed consent.
4. Body mass index (BMI) 18 to 40 kg/m2, inclusive, where BMI (kg/m2) is calculated by body weight (kg)/height2 (m2).
5. Female subjects may be enroled if the following criteria are met:
1. Documented to be surgically sterile or postmenopausal or practicing true abstinence for at least 28 days prior to investigational product (IP) administration until 30 days (duration of ovulatory cycle) after the last IP administration and having a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to the start of IP administration, or
2. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to the start of IP administration.
3. WOCBP must agree to follow instructions for methods of contraception as described in Appendix 18.2 for the duration of treatment with IP plus 5 half-lives of IP (50 hours) plus 30 days (duration of ovulatory cycle) after the last IP administration.
4. Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the study period.
6. Male subjects who are sexually active with WOCBP may be enrolled if they are
1. Documented to be surgically sterile (vasectomy), or
2. Practicing true abstinence for 90 days after the last IP administration, or
3. Males who are sexually active with WOCBP must agree to follow instructions for methods of contraception for the duration of treatment with IP plus 5 half-lives of the IP plus 90 days (duration of sperm turnover) after the last IP administration. In addition, male subjects must be willing to refrain from sperm donation during this time.
7. Azoospermic males are exempt from contraceptive requirements. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements and must still undergo pregnancy testing as described in inclusion criterion #6b.
8. Fully vaccinated for COVID-19 per local regulations and site standard of care (SOC).
2. Diagnosis of plaque psoriasis for ≥3 months at time of screening.
3. Male or female subjects age 18 to 60 years, inclusive, at the time of informed consent.
4. Body mass index (BMI) 18 to 40 kg/m2, inclusive, where BMI (kg/m2) is calculated by body weight (kg)/height2 (m2).
5. Female subjects may be enroled if the following criteria are met:
1. Documented to be surgically sterile or postmenopausal or practicing true abstinence for at least 28 days prior to investigational product (IP) administration until 30 days (duration of ovulatory cycle) after the last IP administration and having a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to the start of IP administration, or
2. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to the start of IP administration.
3. WOCBP must agree to follow instructions for methods of contraception as described in Appendix 18.2 for the duration of treatment with IP plus 5 half-lives of IP (50 hours) plus 30 days (duration of ovulatory cycle) after the last IP administration.
4. Women must not be pregnant, lactating, breastfeeding, or planning pregnancy during the study period.
6. Male subjects who are sexually active with WOCBP may be enrolled if they are
1. Documented to be surgically sterile (vasectomy), or
2. Practicing true abstinence for 90 days after the last IP administration, or
3. Males who are sexually active with WOCBP must agree to follow instructions for methods of contraception for the duration of treatment with IP plus 5 half-lives of the IP plus 90 days (duration of sperm turnover) after the last IP administration. In addition, male subjects must be willing to refrain from sperm donation during this time.
7. Azoospermic males are exempt from contraceptive requirements. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements and must still undergo pregnancy testing as described in inclusion criterion #6b.
8. Fully vaccinated for COVID-19 per local regulations and site standard of care (SOC).
Exclusion Criteria
1. Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic).
2. Diagnosis of psoriatic arthritis, uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with psoriasis for which a subject requires current systemic (oral, subcutaneous, or intravenous \[IV\]) (including corticosteroids, immunosuppressants, biologics) immunosuppressant medical treatment. Certain therapies such as non-steroidal anti-inflammatory drugs may be permitted at the discretion of the medical monitor.
3. Psoriasis affecting the scalp only.
4. Inability to tolerate oral medication.
5. A clinically significant history of gastrointestinal disorder likely to influence absorption of IP.
6. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
7. Participation in a clinical study and/or receipt of an IP within the previous 3 months or 5 half-lives, whichever is longer, before administration of the first dose of IP.
8. History or evidence of active infection and/or febrile illness within 7 days of first administration of IP.
9. History of serious bacterial, fungal, or viral infections that required hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of IP administration.
10. Has received a live vaccine within 60 days of first dose of IP.
11. Current clinical radiographic or laboratory evidence of active tuberculosis (TB), or any history of or significant risk for TB.
12. Any major surgery within 4 weeks of IP administration.
13. Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months.
14. History of malignancy (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence).
15. Has used topical medications/treatments that could affect psoriasis or sPGA evaluation (including, but not limited to, mild to moderate corticosteroids \[eg, hydrocortisone cream, triamcinolone acetonide\], calcineurin inhibitor, calcipotriol, salicylic acid/other keratolytic, coal tar, short contact dithranol) within 4 weeks of the first administration of IP.
16. Has received phototherapy that could affect psoriasis or sPGA evaluation (eg, narrowband ultraviolet B \[UVB\] psoralen \[oral or topical\] with local UVA) within 4 weeks of the first administration of IP.
17. Has received any systemic non-biologic medications/treatments (including, but not limited to, methotrexate, ciclosporin, acitretin, and apremilast) or any systemic biologic medications/treatments (including, but not limited to etanercept, efalizumab, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab) that could affect psoriasis or sPGA evaluation within 4 weeks of the first administration of the IP.
18. Chest X-ray findings suspicious of infection at screening. Subjects may be rescreened and if deemed eligible may be randomized within 28 days of completing an appropriate course of antibiotic treatment for pulmonary infection. If a chest X-ray has been performed within 6 months of the screening visit and the report and results are available, then a chest X-ray is not required at the screening visit.
19. Clinically significant history of previous allergy and/or sensitivity to AX-158 or any of the excipients contained within AX-158.
20. Clinically significant abnormal test results for serum biochemistry, hematology, and/or urine analyses within 28 days prior to first dose administration of the IP:
1. Leukopenia defined as absolute white blood cell count \<3000/mm3 within 28 days of dosing with IP on Day 1.
2. Lymphopenia defined as absolute lymphocyte count \<500/mm3 within 28 days of dosing with IP on Day 1.
3. Neutropenia defined as absolute neutrophil count \<1000/mm3 within 28 days of dosing with IP on Day 1.
4. Moderate to severe thrombocytopenia defined as platelet count \<100,000/mm3 within 28 days of dosing with IP on Day 1.
5. Moderate to severe anemia defined as hemoglobin \<9 g/dL within 28 days of dosing with IP on Day 1.
6. Total serum bilirubin, alkaline phosphatase, aspartate transaminase and alanine transaminase \>1.5 × upper limit of normal (ULN). If total bilirubin is above the ULN and is then fractionated, direct bilirubin must be within normal limits.
21. Subject with a positive urinary drug screen (including alcohol and cotinine) test results, determined within 28 days before the first dose administration of the IP. A positive test result may be repeated at the investigator's discretion.
22. Clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 28 days before first dose of IP including a QRS \>120 ms, PR interval \>220 ms and QT interval corrected using Fredericia's formula \>450 ms.
23. Clinically significant abnormalities in vital signs and physical examination determined within 28 days before first dose of IP.
24. Subjects with a positive COVID-19 test on admission per local regulations and site SOC.
25. Any other condition that, in the investigator's judgement, will substantially increase the risk to the subject if they participate in the study.
2. Diagnosis of psoriatic arthritis, uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with psoriasis for which a subject requires current systemic (oral, subcutaneous, or intravenous \[IV\]) (including corticosteroids, immunosuppressants, biologics) immunosuppressant medical treatment. Certain therapies such as non-steroidal anti-inflammatory drugs may be permitted at the discretion of the medical monitor.
3. Psoriasis affecting the scalp only.
4. Inability to tolerate oral medication.
5. A clinically significant history of gastrointestinal disorder likely to influence absorption of IP.
6. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
7. Participation in a clinical study and/or receipt of an IP within the previous 3 months or 5 half-lives, whichever is longer, before administration of the first dose of IP.
8. History or evidence of active infection and/or febrile illness within 7 days of first administration of IP.
9. History of serious bacterial, fungal, or viral infections that required hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of IP administration.
10. Has received a live vaccine within 60 days of first dose of IP.
11. Current clinical radiographic or laboratory evidence of active tuberculosis (TB), or any history of or significant risk for TB.
12. Any major surgery within 4 weeks of IP administration.
13. Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months.
14. History of malignancy (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence).
15. Has used topical medications/treatments that could affect psoriasis or sPGA evaluation (including, but not limited to, mild to moderate corticosteroids \[eg, hydrocortisone cream, triamcinolone acetonide\], calcineurin inhibitor, calcipotriol, salicylic acid/other keratolytic, coal tar, short contact dithranol) within 4 weeks of the first administration of IP.
16. Has received phototherapy that could affect psoriasis or sPGA evaluation (eg, narrowband ultraviolet B \[UVB\] psoralen \[oral or topical\] with local UVA) within 4 weeks of the first administration of IP.
17. Has received any systemic non-biologic medications/treatments (including, but not limited to, methotrexate, ciclosporin, acitretin, and apremilast) or any systemic biologic medications/treatments (including, but not limited to etanercept, efalizumab, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab) that could affect psoriasis or sPGA evaluation within 4 weeks of the first administration of the IP.
18. Chest X-ray findings suspicious of infection at screening. Subjects may be rescreened and if deemed eligible may be randomized within 28 days of completing an appropriate course of antibiotic treatment for pulmonary infection. If a chest X-ray has been performed within 6 months of the screening visit and the report and results are available, then a chest X-ray is not required at the screening visit.
19. Clinically significant history of previous allergy and/or sensitivity to AX-158 or any of the excipients contained within AX-158.
20. Clinically significant abnormal test results for serum biochemistry, hematology, and/or urine analyses within 28 days prior to first dose administration of the IP:
1. Leukopenia defined as absolute white blood cell count \<3000/mm3 within 28 days of dosing with IP on Day 1.
2. Lymphopenia defined as absolute lymphocyte count \<500/mm3 within 28 days of dosing with IP on Day 1.
3. Neutropenia defined as absolute neutrophil count \<1000/mm3 within 28 days of dosing with IP on Day 1.
4. Moderate to severe thrombocytopenia defined as platelet count \<100,000/mm3 within 28 days of dosing with IP on Day 1.
5. Moderate to severe anemia defined as hemoglobin \<9 g/dL within 28 days of dosing with IP on Day 1.
6. Total serum bilirubin, alkaline phosphatase, aspartate transaminase and alanine transaminase \>1.5 × upper limit of normal (ULN). If total bilirubin is above the ULN and is then fractionated, direct bilirubin must be within normal limits.
21. Subject with a positive urinary drug screen (including alcohol and cotinine) test results, determined within 28 days before the first dose administration of the IP. A positive test result may be repeated at the investigator's discretion.
22. Clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 28 days before first dose of IP including a QRS \>120 ms, PR interval \>220 ms and QT interval corrected using Fredericia's formula \>450 ms.
23. Clinically significant abnormalities in vital signs and physical examination determined within 28 days before first dose of IP.
24. Subjects with a positive COVID-19 test on admission per local regulations and site SOC.
25. Any other condition that, in the investigator's judgement, will substantially increase the risk to the subject if they participate in the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Artax Biopharma Inc
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Accellacare Northamptonshire
Corby, , United Kingdom
Site Status
Accellacare Warwickshire
Coventry, , United Kingdom
Site Status
MEU
Manchester, , United Kingdom
Site Status
Accellacare North London
Northwood, , United Kingdom
Site Status
Accellacare South London
Orpington, , United Kingdom
Site Status
Accellacare Yorkshire
Shipley, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Borroto A, Reyes-Garau D, Jimenez MA, Carrasco E, Moreno B, Martinez-Pasamar S, Cortes JR, Perona A, Abia D, Blanco S, Fuentes M, Arellano I, Lobo J, Heidarieh H, Rueda J, Esteve P, Cibrian D, Martinez-Riano A, Mendoza P, Prieto C, Calleja E, Oeste CL, Orfao A, Fresno M, Sanchez-Madrid F, Alcami A, Bovolenta P, Martin P, Villoslada P, Morreale A, Messeguer A, Alarcon B. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med. 2016 Dec 21;8(370):370ra184. doi: 10.1126/scitranslmed.aaf2140.
Reference Type
BACKGROUND
Roy E, Togbe D, Holdorf AD, Trubetskoy D, Nabti S, Kublbeck G, Klevenz A, Kopp-Schneider A, Leithauser F, Moller P, Bladt F, Hammerling G, Arnold B, Pawson T, Tafuri A. Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15529-34. doi: 10.1073/pnas.1009743107. Epub 2010 Aug 13.
Reference Type
BACKGROUND
Roy E, Togbe D, Holdorf A, Trubetskoy D, Nabti S, Kublbeck G, Schmitt S, Kopp-Schneider A, Leithauser F, Moller P, Bladt F, Hammerling GJ, Arnold B, Pawson T, Tafuri A. Fine tuning of the threshold of T cell selection by the Nck adapters. J Immunol. 2010 Dec 15;185(12):7518-26. doi: 10.4049/jimmunol.1000008. Epub 2010 Nov 15.
Reference Type
BACKGROUND
Gil D, Schamel WW, Montoya M, Sanchez-Madrid F, Alarcon B. Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell. 2002 Jun 28;109(7):901-12. doi: 10.1016/s0092-8674(02)00799-7.
Reference Type
BACKGROUND
Juraske C, Wipa P, Morath A, Hidalgo JV, Hartl FA, Raute K, Oberg HH, Wesch D, Fisch P, Minguet S, Pongcharoen S, Schamel WW. Anti-CD3 Fab Fragments Enhance Tumor Killing by Human gammadelta T Cells Independent of Nck Recruitment to the gammadelta T Cell Antigen Receptor. Front Immunol. 2018 Jul 9;9:1579. doi: 10.3389/fimmu.2018.01579. eCollection 2018.
Reference Type
BACKGROUND
Borroto A, Arellano I, Blanco R, Fuentes M, Orfao A, Dopfer EP, Prouza M, Suchanek M, Schamel WW, Alarcon B. Relevance of Nck-CD3 epsilon interaction for T cell activation in vivo. J Immunol. 2014 Mar 1;192(5):2042-53. doi: 10.4049/jimmunol.1203414. Epub 2014 Jan 27.
Reference Type
BACKGROUND
Borroto A, Arellano I, Dopfer EP, Prouza M, Suchanek M, Fuentes M, Orfao A, Schamel WW, Alarcon B. Nck recruitment to the TCR required for ZAP70 activation during thymic development. J Immunol. 2013 Feb 1;190(3):1103-12. doi: 10.4049/jimmunol.1202055. Epub 2012 Dec 24.
Reference Type
BACKGROUND
Lettau M, Pieper J, Gerneth A, Lengl-Janssen B, Voss M, Linkermann A, Schmidt H, Gelhaus C, Leippe M, Kabelitz D, Janssen O. The adapter protein Nck: role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. Protein Sci. 2010 Apr;19(4):658-69. doi: 10.1002/pro.334.
Reference Type
BACKGROUND
Yiemwattana I, Ngoenkam J, Paensuwan P, Kriangkrai R, Chuenjitkuntaworn B, Pongcharoen S. Essential role of the adaptor protein Nck1 in Jurkat T cell activation and function. Clin Exp Immunol. 2012 Jan;167(1):99-107. doi: 10.1111/j.1365-2249.2011.04494.x.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AX-158-1011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
NCT05223868
COMPLETED
PHASE2
A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis
NCT06972888
COMPLETED
PHASE2
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512
COMPLETED
PHASE3
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
NCT05357755
COMPLETED
PHASE2
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
NCT05120297
COMPLETED
PHASE3
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
NCT02173301
COMPLETED
PHASE2
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
NCT00941031
COMPLETED
PHASE2
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115
ACTIVE_NOT_RECRUITING
PHASE3
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
NCT04999839
COMPLETED
PHASE2
VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
NCT05655299
TERMINATED
PHASE2
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT05364554
COMPLETED
PHASE2
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
NCT01071252
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
NCT06066125
COMPLETED
PHASE3
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
NCT03875508
COMPLETED
PHASE3
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
NCT03589885
COMPLETED
PHASE3
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
NCT02618759
COMPLETED
PHASE3
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
NCT03358290
TERMINATED
PHASE2
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
NCT01132612
COMPLETED
PHASE2
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
NCT04316585
COMPLETED
PHASE1
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject
NCT02303509
COMPLETED
PHASE1
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
ACTIVE_NOT_RECRUITING
PHASE3
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
NCT06875934
ACTIVE_NOT_RECRUITING
PHASE2
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
NCT04908514
COMPLETED
PHASE2
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
NCT04173637
COMPLETED
PHASE2